Lumakras OK’d for patients with KRAS G12C-mutated NSCLC

Create PDF

In a separate release, Qiagen announced the launch of an expanded scope of companion diagnostic claims for the Therascreen KRAS RGQ PCR Kit after it received U.S. regulatory approval as a CDx to aid in the identification of NSCLC patients that may be eligible for treatment with Lumakras.

The Therascreen KRAS kit is the first companion diagnostic to obtain premarket approval from the FDA for use to identify the KRAS G12C mutation in samples of NSCLC tumor tissue.